RE: Today's Finish?14 Aug 2020 16:36
Swimming you really need to go to Specsavers....suggest you read the RNS carefully this time. Especially the bit that say Quote “ where scientists from Hemogenyx Pharmaceuticals will be available to answer questions about their latest research.
The first poster, entitled "High Affinity FLT3-CD3 Bispecific Antibody Effectively Eliminates AML in Humanized Mouse Models", discusses the company's bispecific CDX antibody, designed for the treatment of acute myeloid leukemia ("AML") and concurrent conditioning of the bone marrow niche for hematopoietic stem cell transplantation ("HSCT").
The second poster, entitled "A Novel Anti-FLT3 CAR-T Therapy for Effective Elimination of AML and Conditioning for Hematopoietic Stem Cell Transplantation", discusses the Company's newest cell therapy, chimeric antigen receptor T cells, which express anti-FLT3 antibodies to target and kill AML and condition HSCT.” unquote
Discusses isn’t that talking !!!